Research Papers: Gerotarget (Focus on Aging):
Rapatar a nanoformulation of rapamycin decreases chemicallyinduced benign prostate hyperplasia in rats
PDF | Full Text | How to cite
Metrics: PDF 4028 views | Full Text 4968 views
Ekaterina A. Lesovaya1,*, Kirill I. Kirsanov1,*, Elena E. Antoshina1, Lubov S. Trukhanova1, Tatiana G. Gorkova1, Elena V. Shipaeva2, Ramiz M. Salimov2, Gennady A. Belitsky1, Mikhail V. Blagosklonny3, Marianna G. Yakubovskaya1,** and Olga B. Chernova4,**
1 Department of Chemical Carcinogenesis, Blokhin Cancer Research Center, Moscow, Russia
2 Tartis-Aging LLC, Moscow, Russia
3 Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY, USA
4 Everon Biosciences, Inc., Buffalo, NY, USA
* The first two authors made equal contributions to the study
** The last two authors made equal contributions to the study
Correspondence to:
Marianna Yakubovskaya, email:
Olga B. Chernova, email:
Keywords: gerotarget, aging, benign prostatic hyperplasia, mTOR, rapamycin
Received: December 8, 2014 Accepted: April 15, 2015 Published: April 26, 2015
Abstract
Benign prostatic hyperplasia (BPH) is the most common age-related disease in men. Here we tested the efficacy of Rapatar, a micellar nanoformulation of rapamycin, in two rat models of BPH: testosterone-induced and sulpiride-induced hyperplasia in ventral lobes and lateral/dorsal lobes, respectively. We found that Rapatar prevented hypertrophic and hyperplastic abnormalities and degenerative alterations in both BPH models. Rapatar normalized weight of the lateral lobes in sulpiride-induced BPH, the most relevant animal model of human BPH. Unlike Finasteride, a standard therapy of BPH, Rapatar reduced inflammation caused by sulpiride. No obvious side effects of Rapatar were detected. Our data provide a rationale for clinical trials of Rapatar in patients suffering from BPH.